Category: Uncategorized

KUALA LUMPUR, Jan 26 (Bernama) — Some of the rarest items ever to be offered to the public have been discovered in Australia in shipping containers and storage sheds containing a lifetime collection of militaria from the world over.

Over 10,000 items across many acres constituted a lifelong military collector’s passion. “We were in complete disbelief when we arrived to inspect the collection,” said Lee Hames, Chief Operations Officer for Lloyds Auctioneers and Valuers in Australia.

“These are some of the rarest militaria collectables from WWI and WWII that we have ever seen, there is everything from military tanks to firearms, swords, military uniforms, helmets, boots and heavy artillery.

“As we were uncovering the special collection of militaria, we came across some very rare pieces many of which are ‘one off’ and may be worth significant amounts of money,” he noted in a statement.

The ‘Rod Bellars Collection’ was built by Rod over 60 years, accumulating items from worldwide. Sadly, his recent passing has meant these amazing icons of history have to find new custodians.

“We really hope that museums and libraries and passionate collectors from across the world are successful in securing some of these important pieces of history, so they can be preserved and displayed and educate people for many years into the future,” said Hames.

Items featured across the collection will be sold through 14 separate online auctions which are live now and include tanks, artillery, swords, firearms, helmets, radios, boots, parachutes, military uniforms and much more.

Anyone wanting to take a journey back in time and own some significant pieces of military history can head to www.lloydsauctions.com.au where bidding is open online now.

— BERNAMA

Sets Global Example on Standards for Countries

Rancho Santa Margarita, Calif., Jan 20 (Bernama-GLOBE NEWSWIRE) —Sweegen’s health and wellness commitment through global sugar reduction solutions became stronger after Codex Alimentarius (Codex), the international food standard safety authority, recently adopted the specifications for all four stevia technologies, including Sweegen’s bioconversion.

“The new Codex framework is timely as the benefits of steviol glycosides, the sweet component in the stevia leaf, fit into the broader health and wellness narrative, which is something consumers want to see more of, and global food and beverage manufacturers want greater access to,” said Luca Giannone, senior vice president of sales.

The significance of the adoption is that there is now a more streamlined approach to regional adoption of new production technologies. This will provide greater access to less common and better-tasting steviol glycosides at scale and a more sustainable supply of the sugar-like tasting ingredients.

Sweegen’s support for adopting the “Framework for Stevia Technology” started four years ago as a member of the alliance group, the International Stevia Council (ISC). Adopting the framework was a stevia industry effort and collaboration internationally where Sweegen represented bioconversion technology.

“With this framework, most countries in the world will gradually adopt this standard, and our global stevia footprint can expand more rapidly into countries where we are seeking approval for offering our pure, clean, and great-tasting Signature Bestevia ingredients produced by bioconversion,” said Giannone.

Modern technology advancements, such as bioconversion, produce clean new generation sweetener molecules such as Rebaudiosides M, D, and E, originally found in small quantities in the stevia leaf. Unlike first-generation ingredients like Rebaudioside A, these rebaudiosides impart a clean sugar-like taste with a better sensory profile and are highly sought-after by food and beverage manufacturers in countries where they have regulatory approvals.

“The adopted framework is good news for brands that want greater access to Sweegen’s pure and clean tasting stevia ingredients, Rebs D, E, M, and more,” said Giannone. “By leveraging proprietary bioconversion technology, we start with the stevia leaf, and with the support of enzymes, produce a final product that is a single purified steviol glycoside (not a mixture) that naturally occurs in the stevia leaf.”

Under the new framework, all of Sweegen’s rebaudiosides are approved by Codex. Last year, Sweegen earned regulatory approval for its Signature Bestevia Reb M in Europe, which enables greater flexibility in satisfying regional preferences for sweetness and great taste.

“We welcome the adoption of the Codex framework and the opportunity to support our customers globally with new sugar reduction innovations,” said Steven Chen, Sweegen’s chief executive officer. “Sweegen is proud to be part of this collaborative effort to bring much-needed innovation to the food and beverage industry.” 

###

About Sweegen

Sweegen provides sweet taste solutions for food and beverage manufacturers around the world.

We are on a mission to reduce the sugar and artificial sweeteners in our global diet.  Partnering with customers, we create delicious zero-sugar products that consumers love.  With the best next-generation stevia sweeteners in our portfolio, such as Bestevia® Rebs B, D, E, I, M, and N, along with our deep knowledge of flavor modulators and texturants, Sweegen delivers market-leading solutions that customers want, and consumers prefer. Be well. Choose well.

For more information, please contact info@sweegen.com and visit Sweegen’s website, www.sweegen.com.

Cautionary Statement Concerning Forward-Looking Statements

This press release contains forward-looking statements, including, among other statements, statements regarding the future prospects for Reb M stevia leaf sweetener. These statements are based on current expectations but are subject to certain risks and uncertainties, many of which are difficult to predict and are beyond the control of Sweegen, Inc.

Relevant risks and uncertainties include those referenced in the historic filings of Sweegen, Inc. with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from those expressed in or implied by the forward-looking statements, and therefore should be carefully considered. Sweegen, Inc. assumes no obligation to update any forward-looking statements due to new information or future events or developments.

Attachment

· Greater access to new generation steviol glycosides looks promising after new framework adopted by Codex, an international food safety authority.

Ana Arakelian
Sweegen
949-709-0583
ana.arakelian@sweegen.com

Source: Sweegen

–BERNAMA

New huNOG-EXL EA Model Extends Study Windows Significantly

RENSSELAER, N.Y., Jan 19 (Bernama-GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of the huNOG-EXL EA (Early Access) humanized immune system (HIS) mouse. This product expands Taconic’s widely used HIS portfolio. huNOG-EXL EA significantly lengthens the study window during which a myeloid-lineage HIS mouse model can be used successfully.

Taconic’s huNOG-EXL models support human myeloid and lymphoid cells, making these mice especially useful for immuno-oncology research and other immune-related applications. With the longest lifespan of any myeloid-supportive HIS model, the original huNOG-EXL model (now called huNOG-EXL SA, or Standard Access) has been successfully applied in preclinical drug discovery research since 2016. The huNOG-EXL SA model is provided after a quality control step at 10 weeks post-engraftment. Feedback from users suggests research applications requiring particularly long study timelines or importation into regions with long quarantine periods present experimental and logistical hurdles that can limit the utility of the Standard Access (SA) model.

The new huNOG-EXL EA model removes those challenges by providing access to huNOG-EXL mice soon after engraftment, extending the useful study window. This makes the huNOG-EXL EA ideal for engraftment of slow-growing tumors, longer treatment paradigms, or various study customizations. Early access to an extended myeloid lineage model is also advantageous to researchers who face model importation quarantines, which would otherwise consume a significant portion of the useful study window for these mice. Because the huNOG-EXL EA model is shipped before an engraftment QC step is possible, it is made using cells from donors previously validated to engraft well so as to reduce the risk of engraftment failures.

“The huNOG-EXL EA model meets critical scientific needs for investigators performing immuno-oncology research or studying other immune-related diseases,” said Dr. Michael Seiler, vice president of commercial products at Taconic. “After conducting extensive research and development, along with rigorous beta testing with several industry partners, Taconic is excited to now offer the new model and expand the usefulness of this unique humanized mouse.”

To learn more about Taconic’s huNOG-EXL EA model, please contact us at 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.

About Taconic Biosciences, Inc.

Taconic Biosciences is a fully licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact:

Nancy J Sandy

CEO

608-332-6320

Nancy.Sandy@taconic.com

Source: Taconic Biosciences

–BERNAMA

KUALA LUMPUR, Jan 13 (Bernama) — Adagio Therapeutics Inc, a clinical-stage biopharmaceutical company has summarised recent findings reported in three separate publications that show ADG20, its lead monoclonal antibody (mAb), has neutralisation activity against the Omicron (B.1.1.529) variant of SARS-CoV-2, and outlined initiatives to address current and future SARS-CoV-2 variants of concern.

According to a statement, Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for both the prevention and treatment of COVID-19.

“SARS-CoV-2 is a quickly evolving virus, and at Adagio, we are committed to adapting just as quickly. It is abundantly clear that no single product will fully address the evolving nature of the COVID-19 pandemic, and that multiple preventative and therapeutic solutions are needed,” said co-founder and chief executive officer of Adagio, Tillman Gerngross, Ph.D.

“Based on both in-house data and third-party findings, we are confident that ADG20 can be an important tool in the fight against this virus.”

Adagio is engaging with the U.S. Food and Drug Administration (FDA) regarding potential protocol updates to its global Phase 2/3 clinical trials, including an increased dose of ADG20 for the potential prevention and treatment of COVID-19 resulting from the Omicron variant.

Recently published in vitro studies examined the neutralisation potencies of large panels of mAbs against the Omicron variant in both authentic and pseudovirus assays.

Findings across all three studies show that among mAbs in late-stage clinical development or with Emergency Use Authorization (EUA), ADG20 is one of only a few mAbs that demonstrated neutralising activity against Omicron.

Adagio is continuing evaluation of ADG20 in its EVADE and STAMP clinical trials. Adagio is engaging with the FDA on dosing strategy, including an increased dose of ADG20 and other protocol updates in light of the spread of the Omicron variant.

In addition to its clinical trial updates, Adagio is pursuing multiple strategies to address both Omicron and potential future variants that may emerge.

More details at http://www.adagiotx.com.

— BERNAMA

Rancho Santa Margarita, Calif., Jan 12 (Bernama-GLOBE NEWSWIRE) — Following food authority EFSA’s ban of food additive titanium dioxide (TiO2), Blue California, the producer of natural science-based ingredients, launched novel food-grade whitening agents as a clean-label alternative to replacing potential health risk white colorant titanium dioxide.

“Brands that seek to replace the titanium dioxide white colorant will find many benefits to Blue California’s patent-pending food-grade whitening agents,” said Cuie Yan, Ph.D., vice president of encapsulation. “Our alternative to titanium dioxide is industry-changing with opacifying or whitening effects and excellent sensory benefits with a delicious creamy/rich mouthfeel, and contains proprietary ingredients that may have additional benefits such as supporting cognitive health.”

One of the most widely used food pigments is titanium dioxide (E171), an odorless powder that enhances foods’ white color or opacity. The most common titanium dioxide products are chewing gum, candies, pastries, chocolates, coffee creamers, and cake decorations. Titanium dioxide is also used as a pigment in paints and medicines.

In recent decades, concerns about the risks of titanium dioxide consumption have grown. The Food and Drug Administration (FDA) categorizes titanium dioxide as Generally Recognized as Safe (GRAS) at a maximum of 1% weight, but other organizations have issued warnings.

New governing rules in Europe are in action for producers to reformulate their products during a six-month window of phasing out titanium dioxide (E171). This follows the food authority European Food Safety Authority (EFSA) decision deeming titanium dioxide (E171) as “not safe” in 2021, and now a complete ban in 2022. France suspended the use of titanium dioxide in January 2020.

“Our clean-label, food-grade, and effective whitening agents are heat and pH stable for a variety of applications that match the performance of titanium dioxide yet overcome its safety concerns,” said Yan. “We’ve innovated these solutions as safe alternatives for brands that need to reformulate products rapidly due to government authorities concerns, bans, and phasing out titanium dioxide.”

Blue California’s patent-pending food-grade whitening powders have a similar size in diameter to the traditional titanium dioxide with higher L values (whiter), as shown in Table 1 below:

http://mrem.bernama.com/viewsm.php?idm=42119